Dyne Therapeutics recently announced new long-term clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 demonstrating sustained …
Dyne Therapeutics Announce New Long Terms Clinical Data from DELIVER Trial of DYNE 251Read More
March 26, 2025 by John Marrin
Dyne Therapeutics recently announced new long-term clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 demonstrating sustained …
Dyne Therapeutics Announce New Long Terms Clinical Data from DELIVER Trial of DYNE 251Read More
March 24, 2025 by Mehreen Arif
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of …
March 20, 2025 by John Marrin
This week Capricor Therapeutics announced positive long-term data from its' ongoing HOPE-2 open-label extension (OLE) clinical trial, highlighting the …
March 19, 2025 by John Marrin
We are deeply saddened to learn of the passing of a young man who received ELEVIDYS gene therapy for Duchenne muscular dystrophy. Our hearts go out to …
Action Duchenne’s Statement Regarding Sarepta’s Sad AnnouncementRead More
March 12, 2025 by John Marrin
PepGen's has released an update regarding the CONNECT clinical trials for PGN-EDO51 in Duchenne muscular dystrophy (DMD). PepGen has announced a …
PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMDRead More
March 12, 2025 by John Marrin
Roche have provided an update on the latest top-line results from the second year of their EMBARK Phase 3 clinical trial (NCT05096221) investigating …
Roche Shares Top-line Results from Year Two of the EMBARK Phase 3 Clinical Trial.Read More
March 5, 2025 by John Marrin
Help researchers and mental health professionals at the University of Newcastle better understand how Duchenne muscular dystrophy (DMD) impacts …
Calling all Siblings and Caregivers of Individuals with DuchenneRead More
March 5, 2025 by John Marrin
DMD Care UK will host a webinar to summarise the evidence for vamorolone as a treatment for Duchenne muscular dystrophy (DMD), and provide an …
Vamorolone for Duchenne Muscular Dystrophy: A Summary of Evidence So FarRead More
February 28, 2025 by Lizzie Deeble
Dear Friends, Supporters, and Advocates, On Rare Disease Day 2025, we stand together to raise awareness, celebrate our community, and drive …
Open Letter from the Chair and CEO of Action Duchenne for Rare Disease Day 2025Read More
February 26, 2025 by John Marrin
We're excited to share news that Solid Biosciences has released initial data from its Phase 1/2 INSPIRE DUCHENNE clinical trial, assessing the safety …
Solid Biosciences Shares 90 Day Update From SGT-003 Gene Therapy TrialRead More
February 25, 2025 by Lizzie Deeble
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44 Entrada Therapeutics, today announced that the United States Food and …
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44Read More
February 14, 2025 by Lizzie Deeble
Family Science Education Day and Charity Dinner Dance Join us for a Family Day at Birmingham's Think Tank Science Museum followed by a Charity …
Family Science Education Day and Charity Dinner DanceRead More
Action Duchenne
Wellesley House
Duke of Wellington Avenue Royal Arsenal
London
SE18 6SS
07535 498 506
info@actionduchenne.org